Company intelligence / Profile preview
Rebirthel Co., Ltd.
Kyoto-city, Kyoto, Japanrebirthel.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Rebirthel has developed a proprietary platform for generating universal, off-the-shelf cytotoxic T lymphocytes from pluripotent stem cells. These therapies are designed to be mass-produced, stored, and administered to any patient without the need for autologous cell collection. The company’s technology has demonstrated high cytotoxic activity in vitro and aims to address unmet needs in cancer immunotherapy as well as other immune-related conditions. Clinical results have not yet been published; programs are at preclinical or early clinical stages.
- Therapeutic areas
- Infectious DiseasesImmunologyOncology
- Modalities
- Allogeneic T cell therapyiPSC-derived T cells (induced pluripotent stem cell-derived)Genetically engineered T cells (including CAR-T and TCR-T)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Otsuka Pharmaceutical Co., Ltd. – exclusive commercial licensing agreement for iPSC-derived CAR-T/TCR-T production technology across multiple therapeutic areas worldwideJoint research with Kyoto University’s Institute for Frontier Life and Medical Sciences / Prof. Hiroshi Kawamoto’s labOther partners/investors include FUJIFILM Holdings Corporation, SCREEN Holdings Co., Ltd., Toho Holdings Co., Ltd.
Beyond the preview
Go deeper on Rebirthel Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rebirthel Co., Ltd..